FDA Approves Liposomal Amikacin Inhalation Suspension for Bacterial Lung Disease
September 29th 2018The US Food and Drug Administration has approved Arikayce for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a limited population of patients who do not respond to conventional treatment.
HIV Impacts Neurocognition in Resource-Limited Settings
September 27th 2018Despite big advances in the field of HIV treatment, including streamlined drug regimens that help infected people achieve normal or near-normal lifespans, living with HIV often means dealing with neurocognitive impairment of some kind.